Ipsen SA · EURONEXT:IPN
Ipsen SA — 2009 Europe Conference – Piper Jaffray
32 slides from Ipsen SA's conference presentation, Jun 23, 2009
Slide 1: Ready for further growth
Ready for further growth 2009 Europe Conference – Piper Jaffray London, 23rd June 2009 Mr David Schilansky – Investor Relations and Financial Officer Mr Pierre kemula – Investor Relations Manager Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
Slide 2: Ipsen today: a global, innovation driven, specialty pharma
Introduction Ipsen today : a global, innovation driven, specialty pharma PRIMARY CARE SPECIALTY CARE OPTIMISE returns of this A global business to GROW mostly French business A transactional model ONCOLOGY 27% GI 19% Decapeptyl® ENDOCRINOLOGY 17% Cognitive disorders 13% Somatuline®, Nutropin®, Incre
Slide 3: Ipsen has consistently delivered on its strategic milestones
Ipsen has consistently delivered on its strategic milestones… 3 months Launches in the UK Debiopharm LCM Decapeptyl®® Decapeptyl formulation and Germany agreement 6M filing ~ 48% of European market for 6M Taspoglutide Taspoglutide Ph I Roche Opt-in Ph III Pipeline OBI-1 Ph I Octagen Assets Ph II / I
Slide 4: An increasingly transactional model; Ipsen today
An increasingly transactional model ENDOCRINOLOGY ONCOLOGY NEUROLOGY PRIMARY CARE 2003 - 2005 2006- 2008 7 Ipsen – Corporate Presentation Ipsen today…. Î Resilience of business in a difficult macro-economic environment Î A strong and profitable specialty care growth engine Î Substantial growth oppor
Slide 5: Truly Differentiated R&D Capabilities
Truly Differentiated R&D Capabilities Defining Ipsen’s competitive edge in R&D Hormones provide well defined templates with matching targets both novel or validated Resident know how based on the integration of basic discovery technologies Technologies Medicinal chemistry Delivery systems Steroids p
Slide 6: Somatuline Depot: an improved presentation
Somatuline® Depot: an improved presentation Sandostatin LAR® Somatuline® Autogel® 2.0 ml 0.3 ml – 0.5 ml Administration Intramuscular Subcutaneous Powder vial + solvent filled Presentation Pre-filled syringe syringe + 2 needles 10 steps needed to Ready to use Injection technique reconstitute Self ad
Slide 7: Strong growth drivers
Strong growth drivers North America, a strong growth platform going forward US Endocrinology platform Sales in excess of (Somatuline® Depot; Increlex®) $250 million 2012 US Neurology platform Sales in excess of (Apokyn®; DysportTM) $50 million Haematology World wide sales in excess of At peak (OBI-1
Slide 8: Review of Ipsen's growth drivers
Review of Ipsen’s growth drivers Product Indications Progress Current Market value NET - US Ph III ~ $400 million 1) Somatuline®® Somatuline Non Functioning NET- WW Ph III > $400 million 2) BIM Acromegaly, NET, other PhII > $1.5 billion 3) Endocrinology BIM 23A760 23A760 indications - WW GH GH –– IG
Slide 9: Q1 top line evolution; Our 2009 Objectives
Q1 Top line evolution Drug Sales by therapeutic area Group Sales by region (excludes Drug Related Sales) (Includes Drug Related Sales) +5.4% Performance growth (1) : +5.8% +6.8% Performance growth (1) : +7.3% 138.7 +8.2% 134.8 143.8 +2.9% 132.9 (15.5)% 50.8 60.1 +4.7% 98.9 94.5 +27.3% 54.5 42.8 n.m.
Slide 10: Potentially a strong cash generation for 2009
Potentially a strong cash generation for 2009 2008 closing net cash position 66.2 M€ Medicis, DysportTM $75 million to be paid imminently (Approval by FDA) Bayer settlement ~ €36 million (Disputed royalty revenue stream) Adenuric: out licensing deal with partner Potential additional cash elements Ot
Slide 11: You will hear from us in the months to come
You have and you will hear from us in the months to come… Adenuric® Decapeptyl® 6 Months Partnership(s) and Approval launches BIM-23A760 Toremifene Citrate 80 mg 9 Primary care products Phase II initiation European filing In-licensing deal(s) OBI-1 Phase III initiation Azzalure® 9 Approval in Europe
Slide 12: Ipsen's 2008 acromegaly market share; Somatuline Depot
A unique focus on pituitary disorders and hormone dependent diseases A strong franchise Hypothalamus A range of products addressing today - + Short Stature, Acromegaly and NET SST GHRH • High morbi-mortality Pituitary • Debilitating pathologies GH ss • High unmet medical needs de ce fic ex GH ie
Slide 13: Somatuline offers life cycle growth opportunities; Increlex in the US
- + + Somatuline® offers significant life cycle growth opportunities Relative NET market size (indicative) Ipsen’s Phase III underway current positioning Last patient targeted for 2009 (n=200) Functionally active NETs Europe Europe Non functioning NETs & & Symptoms due to Incidental finding/ RoW RoW
Slide 14: NutropinAq gaining market share; portfolio synergy with Increlex
- + + NutropinAq® in Ipsen territories is steadily gaining market share GH market NutropinAq® attributes CAGR1 05-08 1st liquid formulation launched WW Total GH market: ~+6% NutropinAq®: >80% A simple and user friendly pen In million Mgs Market share 25 6% An experienced post marketing surveil
Slide 15: Redefining the treatment of short stature; endocrinology pipeline
- + + Ipsen is redefining the treatment of short stature Non-GH Deficient Short Stature: 100,000 patients in the US GH Deficiency 1 20,000 patients 2 IGF-I Deficiency 30,000 patients 3 Severe “True” Primary Primary IGFD IGFD GHD 70,000 24,000 6,000 MS301: Study in Primary IGFD 90% GH 15% GH MS30
Slide 16: Confirming Ipsen as a leader in hormone dependent cancers
Confirming Ipsen as a leader in the field of hormone dependent cancers Confirming Ipsen as a leader in Hormone Dependent Cancers Endometrial Cancer Ovarian Cancer Breast Cancer Ipsen oncology New Medical Entities NET Prostate Cancer 32 Ipsen – Corporate Presentation
Slide 17: Decapeptyl 3 months formulation: a competitive product profile
Decapeptyl® 3 months formulation: a competitive product profile Marketed 1 month (1M) and 3 month (3M) formulations Formulation Maintenance of castrate testosterone levels at 3M in 98% of patients1 and efficacy At 3M, 91% decrease of PSA levels, showing tumor control Local tolerance/ IM rout
Slide 18: Decapeptyl 6 month formulation; A promising Oncology pipeline
Decapeptyl® 6 month formulation: a more differentiated product profile Comparable efficacy to 1 and 3 months formulation • Castration levels (testosterone) Efficacy • Disease control (PSA) Local Limited local side effects (6.7% of patients ) Tolerance Storage and Storage at room temperature (n
Slide 19: BN-83495: higher prevalence diseases and unmet needs
BN-83495 Moving up to higher prevalence diseases and higher unmet medical needs 5 year survival stage IV disease 35% 30% Prostate 25% 20% 15% Breast 10% Ovarian 5% Endometrial 0% Incidence 0 50,000 100,000 150,000 200,000 250,000 EU G5 Ipsen New Medical Entities: multi targeted agents aiming at larg
Slide 20: BN-83495: first clinical study in Breast Cancer patients
BN-83495 First clinical study in Breast Cancer patients STS inhibition leads to significant reduction in circulating steroids and induces clinical benefit** First clinical study CR UK * - Daily x 5 dosing A 5 mg dose B 20 mg dose PBL STS PBL STS DHEA DHEA A 0 NH2 Adione Adione S % baseline Adiol % b
Slide 21: Near-term milestones in hormone dependent cancers
Confirming Ipsen as a leader in Hormone Dependent Cancers Endometrial Cancer BN-83495 Initiation PII in 2009 Ovarian Cancer BN-83495 Initiation PII in 2009 Breast Cancer BN-83495 Initiation PII in 2009 Ipsen oncology New NET in the US Medical Entities Initiation PIII in 2009 Prostate Cancer Decapept
Slide 22: A specific therapeutic focus; Dysport approved ex-US
A specific therapeutic focus Ipsen focus: from Neuromuscular Disorders to Neurology Aesthetic field Reloxin® - US DysportTM US expansion 9 a > €140 m brand DysportTM Licensing-in marketed in 73 countries Azzalure® - EU Apokyn® R&D Partnered out Cash from alliances fuels growth strategy (30% of Medic
Slide 23: Dysport: launched in 1991, approved in 73 countries
DysportTM: launched in 1991, approved in 73 countries Market share in medical indications GER 47% UK 52% F 39% IT 43% In dark blue, countries where Dysport® is marketed 45 Ipsen – Corporate Presentation Sources: IMS, Insight Health/ODV, Ipsen estimates A good track record at catching-up market share
Slide 24: Dysport in the US: a step toward a global neurology franchise
DysportTM in the US: a step further toward a global neurology franchise 1. DysportTM: a proven track record and field proven product 2. A true global product 3. A unique focus on medical use 4. Focus on US opportunity – strong positioning with well prepared launch • Sound value proposition: the medi
Slide 25: OBI-1: agent targeting acquired and congenital hemophilia
An agent targeting both acquired and congenital hemophilia Congenital hemophilia A Acquired hemophilia with inhibitors to human FVIII Acquired factor VIII inhibitor Affects 1:4000 male births Affects 1 to 2 individuals in 1,000,000, predominantly in older individuals The development of neutral
Slide 26: Appendix 1: Evolution of our 2008 financial objectives
A highly specialized hospital product addressing unmet need First biologics to conclude Phase 2 resulting from strategic biotechnology platform Patent protection until 2023 in Europe and US World-wide commercialization rights Lean commercial infrastructure A commercial potential in excess of US$200
Slide 27: Evolution of our 2008 financial objectives
Evolution of our 2008 financial objectives Strong commercial Tercica performance and closing Ginkor Fort® success FY FY07 07 H1 H108 08 Q3 Q308 08 February February August August October October 2008 2008 2008 2008 2008 2008 Bayer Other revenues growth 13.0 - 16.0% 25.0 - 30.0% dispute (4.0) - (9.0)
Slide 28: Definitions; Our financial objectives have been met
‘Standalone’ Group sales: Group sales at constant currency, less its North American fourth quarter 2008 consolidated sales ‘Performance’ or ‘underlying’ growth: Group sales growth at constant currency, excluding the sales of Ginkor Fort® in 2007 and 2008 as the product was divested on January 1, 200
Slide 29: Key elements to take into consideration in 2008 over 2007
Key elements to take into consideration in 2008 over 2007 2007 2008 Ginkor Fort® €37.0 m €14.0 m divestment sales sales Consolidation of US Q3&Q4 consolidated Sales acquisitions - sales of €8.1 m 80 basis points negative impact Currency headwind on sales growth €25.0 m Dispute with Bayer - “miss” Ot
Slide 30: Top line evolution; P&L above EBIT
Top line evolution Sales by therapeutic area Sales by region +5.5% +5.5% Performance growth (1) : +8.2% Performance growth (1) : +8.2% 493.7 +12.0% 553.2 559.5 564.3 (0.8)% (2.6)% 208.1 +13.5% 236.2 393.2 383.1 148.1 +18,4% 175.3 Incl. €8.1 m for US (2) +3.4% 2007 2008 2007 2008 Others Primary care
Slide 31: P&L operating result and margin; below EBIT
P&L – operating result and margin “Stand-alone” (excluding all impacts of US acquisitions) €207.7 m 21.6% Excluding US acquisitions one-off costs €186.7 m 19.2% As reported €180.1 m 18.5% 61 Ipsen – Corporate Presentation Margins expressed in % of sales P&L – below EBIT Financial result (€m) Effecti
Slide 32: Balance Sheet evolution; Cash flow statement
Balance Sheet evolution - In million of euros Assets - In million of euros Liabilities 31 Dec 07 31 Dec 08 31 Dec 07 31 Dec 08 Goodwill 189.0 351.7 Equity 799.9 866.9 Property, plans & equipments 221.9 237.9 Minority interests 1.2 1.6 Intangible assets 89.2 163.9 Total equity 801.1 868.5 Other non-c